<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred twelve patients with geriatric <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), refractory or relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RAEBt) were entered into this study to receive CAG (aclarubicin and low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> [Ara-C]in combination with granulocyte colony-stimulating factor [G-CSF]) with the objective of evaluating the efficacy and tolerance of this regimen </plain></SENT>
<SENT sid="1" pm="."><plain>Low-dose Ara-C was given subcutaneously at a dosage of 10 mg/m2 every 12 hours on days 1 to 14 </plain></SENT>
<SENT sid="2" pm="."><plain>Aclarubicin was administered intravenously at a dosage of 14 mg/m2 per day on days 1 to 4 (CAG regimen A) or 7 mg/m2 on days 1 to 8 (CAG regimen B) </plain></SENT>
<SENT sid="3" pm="."><plain>Recombinant G-CSF was given subcutaneously at a dosage of 200 3g/m2 per day on days 1 to 14 </plain></SENT>
<SENT sid="4" pm="."><plain>We demonstrated comparable overall complete remission rates for the 4 groups of patients: 30.8% (8/26) in the elderly patients, 48.4% (30/62) in the refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients, 44.4% (8/18) in the relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients, and 38.5% (5/13) in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RAEBt patients </plain></SENT>
<SENT sid="5" pm="."><plain>Of the 52 patients followed up, the 12-month progression-free survival (PFS) and overall survival (OS) rates estimated by the Kaplan-Meier method were 40.73% 3 8.15% and 42.85% 3 8.23%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The median PFS and OS times were 9.0 3 2.2 months and 11.0 3 1.6 months, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Toxic effects were very rare and mainly consisted of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> due to <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e>; approximately 70% to 80% of patients had <z:hpo ids='HP_0001875'>neutropenia</z:hpo> or <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> that exceeded National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute grade II </plain></SENT>
<SENT sid="8" pm="."><plain>Nonhematologic toxicities were not observed in this study </plain></SENT>
<SENT sid="9" pm="."><plain>The CAG regimen seems promising, with acceptable toxicity, for the treatment of various categories of poor-prognosis <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RAEBt </plain></SENT>
</text></document>